Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction).Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [213]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [178]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
(2000) · PubMed · Cited by 2,095
Research works printed but not linked: 2
- Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A
- 2002, Diabetic nephropathy, Diabetes Care, 25, S85
Cited by
Items 601–700 of 1,001
Metabolic safety of antihypertensive drugs: Myth versus reality
Stas, S. N., Appesh, L., & Sowers, J. R. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0086-8 · Cited by 19
Optimal care of patients with type 2 diabetes mellitus and coronary artery disease
Frye, R. L. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.015 · Cited by 21
Srivastava, P., Calafiore, P. A., MacIsaac, R. J., Hare, D. L., Jerums, G., & Burrell, L. M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01274.x · Cited by 22
Schindler, C. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708094309 · Cited by 20
de Pablos-Velasco, P. L., Martínez-Martín, F. J., Rodríguez-Pérez, F., Ruilope, L. M., & Robles, R. G. (2002) · Journal of Hypertension · doi:10.1097/00004872-200210000-00015 · Cited by 22
Obesity and kidney protection.
Chandra, A., Biersmith, M. A., & Tolouian, R. (2014) · PubMed Central · doi:10.12860/jnp.2014.18 · Cited by 22
Wahlberg, K. J., Arnold, M. E., Lustgarten, D. L., & Meyer, M. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.07.008 · Cited by 23
Pfaue, A., Schuler, P. J., Mayer, B., Hoffmann, T. K., Greve, J., & Hahn, J. (2019) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2019.1698259 · Cited by 21
Bazán, H. A., Smith, T. A., Donovan, M. J., & Sternbergh, W. C. (2014) · PubMed Central · Cited by 22
Reis, K. A., Ebinç, F. A., Koç, E., Demirci, H., Erten, Y., Güz, G., Derici, Ü., Bali, M., Söylemezoğlu, O., Arınsoy, T., et al. (2011) · Renal Failure · doi:10.3109/0886022x.2011.568133 · Cited by 19
Magnusson, M., Jovinge, S. V., Shahgaldi, K., Israelsson, B., Groop, L., & Melander, O. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-2 · Cited by 22
Managing hypertension in cardiology practice according to risk profile
Volpe, M., & Tocci, G. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01821.x · Cited by 22
Shin, J., Palta, M., Djamali, A., Kaufman, D. B., & Astor, B. C. (2015) · Transplantation · doi:10.1097/tp.0000000000000938 · Cited by 22
Chen, L., Ren, Z.-P., Wei, X., Wang, S., Wang, Y., Cheng, Y., Gao, H., & Liu, H. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.028 · Cited by 20
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 27
Lenstrup, M., Kjærgaard, J., Petersen, C., Kjær, A., & Hassager, C. (2006) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510600892233 · Cited by 20
Krum, H., Skiba, M. A., & Gilbert, R. E. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01023.x · Cited by 21
Rosner, M. H., & Okusa, M. D. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1025 · Cited by 19
AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan
Ferrario, C. M., & Moore, M. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003017 · Cited by 25
A cardiologist view of vascular disease in diabetes
Lockhart, C., Hamilton, P., McVeigh, K., & McVeigh, G. E. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00727.x · Cited by 19
Cerbai, E., Paoli, P. D., Sartiani, L., Lonardo, G., & Mugelli, A. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200305000-00019 · Cited by 19
Epidemiology of Type 2 Diabetes
Ronald, C. W., & Tong, P. C. Y. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch4 · Cited by 24
ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?
Lewis, E. J., & Lewis, J. B. (2004) · PubMed · Cited by 18
Antitumor Therapy Targeting the Tumor Microenvironment
Gao, Y., Pan, Z., Li, H., & Wang, F. (2023) · Journal of Oncology · doi:10.1155/2023/6886135 · Cited by 23
Shin, J., Park, J. B., Kim, K., Kim, J. H., Yang, D. H., Pyun, W. B., Kim, Y. G., Kim, G., & Chae, S. C. (2015) · Clinical Hypertension · doi:10.1186/s40885-014-0014-1 · Cited by 19
Hitomi, H., Kaifu, K., Fujita, Y., Sofue, T., Nakano, D., Moriwaki, K., Hara, T., Kiyomoto, H., Kohno, M., Kobori, H., et al. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.114 · Cited by 21
Managing hypertension in the elderly: a common chronic disease with increasing age.
Qt, N., Anderson, Sanders, L., & Nguyen, L. D. (2012) · PubMed · Cited by 54
Rizvi, A. A. (2017) · PubMed · Cited by 18
Laakso, M. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90035-6 · Cited by 24
Progression of Chronic Kidney Disease: Mechanisms and Interventions in Retardation
Balasubramanian, S. (2013) · Apollo Medicine · doi:10.1016/j.apme.2013.01.009 · Cited by 25
Naik, A. D., Issac, T. T., Street, R. L., & Kunik, M. E. (2007) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2007.05.070026 · Cited by 17
Macrovascular Complications of Diabetes Mellitus
Nuzum, D. S., & Merz, T. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190008326444 · Cited by 18
White, C. J., Beckman, J. A., Cambria, R. P., Comerota, A. J., Gray, W. A., Hobson, R. W., Iyer, S. S., & for Writing Group 5 (2008) · Circulation · doi:10.1161/circulationaha.108.191175 · Cited by 19
Cubbon, R. M., Kahn, M., & Kearney, M. T. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01646.x · Cited by 20
Schäfer, A., Flierl, U., Vogt, C., Menninger, S., Tas, P. W. L., Ertl, G., & Bauersachs, J. K. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.05.009 · Cited by 18
Gæde, P., & Pedersen, O. (2004) · Annals medicus · doi:10.1080/07853890410033612 · Cited by 20
NT‐proBNP in normoalbuminuric patients with Type 2 diabetes mellitus
Andersen, N. H., Poulsen, S. H., Knudsen, S. T., Heickendorff, L., & Mogensen, C. E. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01396.x · Cited by 18
Mitterbauer, C., Heinze, G., Kainz, A., Kramár, R., Hörl, W. H., & Oberbauer, R. W. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm864 · Cited by 19
Ganne, S., Arora, S., Dotsenko, O., McFarlane, S. I., & Whaley‐Connell, A. T. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0033-3 · Cited by 21
Carotid intima-media thickness and cognitive decline: what does it mean for prevention of dementia?
Spence, J. D. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.012 · Cited by 20
New developments in type 2 diabetes mellitus: Combination therapy with a thiazolidinedione
Braunstein, S. N. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80195-9 · Cited by 20
Nilsson, P. M., Cederholm, J., Guðbjörnsdóttir, S., & Eliasson, B. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000188733.60345.78 · Cited by 17
Kunimura, A., Himuro, N., Fujiyoshi, A., Segawa, H., Ohnishi, H., & Saitoh, S. (2019) · Hypertension Research · doi:10.1038/s41440-019-0234-6 · Cited by 17
Risk factors for cardiovascular disease in women with diabetes
Maric, C. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.11.007 · Cited by 17
de Pablos-Velasco, P. L., González-Albarrán, O., Estopiñán, V., Khanbhai, A., & in representation of the TARMIDAS Group (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002214 · Cited by 19
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 39
Hypertension and Cardiovascular Disease
Whaley‐Connell, A. T., Sowers, K. M. R., & Sowers, J. R. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-153-6_28 · Cited by 19
Hypertension and stroke: an appraisal of the evidence and implications for clinical management
Lackland, D. T., Voeks, J. H., & Boan, A. D. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2016.1143359 · Cited by 20
Burggraaf, B., & Cabezas, M. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.04.017 · Cited by 18
Shunan, F., Jiqing, Y., & Xue, D. (2018) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320318803495 · Cited by 17
Garlo, K. G., Bates, D. W., Seger, D. L., Fiskio, J. M., & Charytan, D. M. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3874 · Cited by 20
the directors of the JCS, J., Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00471-5 · Cited by 17
What can we learn from the recent blood glucose lowering megatrials?
Chan, J. C. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00063.x · Cited by 17
Kjeldsen, S. E., Devereux, R. B., Hille, D. A., Lyle, P. A., Dahlöf, B., Julius, S., Edelman, J. M., Snapinn, S. M., Fairé, U. D., Fyhrquist, F., et al. (2009) · Blood Pressure · doi:10.3109/08037050903460590 · Cited by 20
Self-citationIbrahim, S. L., Jiroutek, M. R., Holland, M. A., & Sutton, B. S. (2016) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2016.01.005 · Cited by 18
Prévention des accidents vasculaires cérébraux
Niclot, P., Cohen, A. A., Crassard, I., & Bousser, M.-G. (2004) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(03)00133-7 · Cited by 25
Husarek, K. E., Katz, P. S., Trask, A. J., Galantowicz, M. L., Cismowski, M. J., & Lucchesi, P. A. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.06.013 · Cited by 18
Ethnic Differences in the Treatment and Control of Hypertension in Patients With Diabetes
RIEHLE, J., Lackland, D. T., Okonofua, E. C., Hendrix, K. H., & Egan, B. M. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04542.x · Cited by 18
Diuretics: drugs of choice for the initial management of patients with hypertension
Fuchs, F. D. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.1.35 · Cited by 21
Bertoméu, V., Fácila, L., González‐Juanatey, J. R., Cea‐Calvo, L., Aznar, J., Mazón, P., & Bertomeu‐González, V. (2007) · Revista Española de Cardiología · doi:10.1157/13113931 · Cited by 16
The role of blood pressure lowering before and after stroke.
Donnan, G. A., Davis, S. M., & Thrift, A. G. (2003) · PubMed · doi:10.1097/01.wco.0000053585.70044.2c · Cited by 17
Diastolic Pressure in Type 2 Diabetes
Osher, E., & Stern, N. (2008) · Diabetes Care · doi:10.2337/dc08-s262 · Cited by 20
Reuter, H., Adam, C., Grönke, S., Zobel, C., Frank, K. F., Müller‐Ehmsen, J., Brabender, J., & Schwinger, R. H. G. (2006) · Diabetologia · doi:10.1007/s00125-006-0444-8 · Cited by 16
Sandset, E. C., Murray, G. D., Boysen, G., Jatužis, D., Kõrv, J., Lüders, S., Richter, P., Roine, R. O., Terént, A., Thijs, V., et al. (2010) · International Journal of Stroke · doi:10.1111/j.1747-4949.2010.00473.x · Cited by 16
Rajtík, T., Čarnická, S., Szobi, A., Giricz, Z., O‐Uchi, J., Hassova, V., Švec, P., Ferdinandy, P., Ravíngerová, T., & Adameová, A. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.12.024 · Cited by 19
Telmisartan Improves Cardiometabolic Profile in Obese Patients with Arterial Hypertension
Kubik, M., Chudek, J. T., Adamczak, M., & Więcek, A. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000334951 · Cited by 18
Why Is Blood Pressure So Hard to Control in Patients With Type 2 Diabetes?
Kazuo Eguchi MD, P., Pickering, T. G., & Kario, K. (2007) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2007.06124.x · Cited by 16
Fixed-dose triple-combination treatments in the management of hypertension.
Ram, C. V. S. (2013) · PubMed · Cited by 20
Voroneanu, L. E., Siriopol, D. C., Dumea, R., Bădărau, S., Kanbay, M., Afşar, B., Gavrilovici, C., & Covic, A. C. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1697-5 · Cited by 16
Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall
Lunder, M., Janić, M., & Šabović, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180206113755 · Cited by 21
Cardiovascular Prevention in Patients with Diabetes and Prediabetes
Anselmino, M., Gohlke, H., Mellbin, L., & Rydén, L. (2008) · Herz · doi:10.1007/s00059-008-3105-5 · Cited by 17
Crook, E. D., & Preddie, D. C. (2002) · PubMed · Cited by 16
Andersen, N. H., & Mogensen, C. E. (2002) · Current Hypertension Reports · doi:10.1007/s11906-002-0070-x · Cited by 16
Narkiewicz, K. (2007) · Blood Pressure · doi:10.1080/08038020701561687 · Cited by 16
Calcium Antagonists in Patients with Type 2 Diabetes and Hypertension
McFarlane, S. I., Farag, A., & Sowers, J. R. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00109.x · Cited by 17
Escobar, C., Barrios, V., Calderón, A., Barrios, S., Echarri, R., Navarro‐Cid, J., Ferrer, E., & Fernández, R. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07596.x · Cited by 16
Trends in Blood pressure Control in Hypertensive Patients with Diabetes Mellitus in Japan
Hirose, H., & Saito, I. (2003) · Hypertension Research · doi:10.1291/hypres.26.717 · Cited by 16
Angiotensin II Receptor Antagonists: A New Way to Deal with Stroke Prevention in Hypertension
Tocci, G., Giovannelli, F., & Facciolo, C. (2007) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/00151642-200714010-00006 · Cited by 16
Igarashi, M., Hirata, A., Nozaki, H., Kadomoto, Y., & Tominaga, M. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.06.032 · Cited by 21
Prevención y tratamiento de la cardiopatía isquémica en pacientes con diabetes mellitus
Bueno, H. (2002) · Revista Española de Cardiología · doi:10.1016/s0300-8932(02)76736-5 · Cited by 18
Treatment of hypertension in diabetes: what is the best therapeutic option?
Aksnes, T. A., Skårn, S. N., & Kjeldsen, S. E. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.59 · Cited by 18
Self-citationNomura, S., & Komuro, I. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.11.010 · Cited by 16
Thiazide Diuretics and β‐Blockers in the Treatment of Hypertension in Diabetes Mellitus
Sander, G. E., & Giles, T. D. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00454.x · Cited by 16
Kim, C., Kim, M. Y., Kang, D. R., Kim, J., Park, J. B., & on behalf of the K-MetS study investigators (2013) · Pulse · doi:10.1159/000360965 · Cited by 16
Kuwashiro, T., Kamouchi, M., Ago, T., Hata, J., Sugimori, H., & Kitazono, T. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.09.012 · Cited by 16
Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus
Reboldi, G., Gentile, G., Angeli, F., & Verdecchia, P. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.133 · Cited by 18
Min, S. H., Kong, S. H., Lee, J.-E., Lee, D., Oh, T. J., Kim, K. M., Park, K. S., Jang, H. C., & Lim, S. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.07.002 · Cited by 15
Park, C. G., Youn, H., Chae, S.-C., Yang, J.-Y., Kim, M. H., Hong, T., Kim, C., Kim, J., Hong, B., Jeong, J. W., et al. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11597170-000000000-00000 · Cited by 16
Uchida, J., Machida, Y., Iwai, T., Iguchi, T., Kamada, Y., Naganuma, T., Kumada, N., Kim, T., Kawashima, H., & Nakatani, T. (2011) · Journal of Nephrology · doi:10.5301/jn.2011.6235 · Cited by 16
Combination ACE Inhibitor and Angiotensin Receptor Blocker Therapy—Future Considerations
Sica, D. A. (2007) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.6359.x · Cited by 18
Matsushita, K., Muramatsu, T., Kondo, T., Maeda, K., Shintani, S., & Murohara, T. (2010) · Journal of Cardiology · doi:10.1016/j.jjcc.2010.03.004 · Cited by 15
Losartan and diabetic nephropathy: commentaries on the RENAAL study
Fisman, E. Z., Tenenbaum, A., & Motro, M. (2002) · Cardiovascular Diabetology · doi:10.1186/1475-2840-1-2 · Cited by 15
Role of insulin resistance in essential hypertension
Tarray, R., Saleem, S. M., Afroze, D., Yousuf, I., Gulnar, A., Laway, B. A., & Verma, S. (2014) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000032 · Cited by 16
Prakoso, D., Tate, M., Blasio, M. J. D., & Ritchie, R. H. (2021) · Clinical Science · doi:10.1042/cs20210052 · Cited by 17
Ali, I., Akman, D., Bruun, N. E., Køber, L., Brendorp, B., Ottesen, M. M., Møller, J. E., & Torp-Pedersen, C. T. (2004) · Clinical Cardiology · doi:10.1002/clc.4960270504 · Cited by 15
Renin-Angiotensin-Aldosterone System Blockade in Diabetes: Role of Direct Renin Inhibitors
Estacio, R. O. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.2000 · Cited by 20
Management of cardiovascular risk with RAS inhibitor/CCB combination therapy
Dahlöf, B. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.88 · Cited by 18
Self-citationHypertension in the Elderly: A Japanese Perspective
Ogihara, T., & Rakugi, H. (2005) · Drugs & Aging · doi:10.2165/00002512-200522040-00003 · Cited by 21
Choi, S. M., Seo, M. J., Kang, K. K., Kim, J. H., Ahn, B. O., & Yoo, M. (2009) · Archives of Pharmacal Research · doi:10.1007/s12272-009-1307-x · Cited by 15
Barbey, F., Brakch, N., Linhart, A., Jeanrenaud, X., Palecek, T., Bultas, J., Burnier, M., & Hayoz, D. (2006) · Acta Paediatrica · doi:10.1080/08035320600618924 · Cited by 54
Metadata
- Authors
- Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S.
- Affiliations
- University Hospital of Umeå (SE)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- University of Michigan (US)
- Oslo University Hospital (NO)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lindholm, Lars H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 1004-1010
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1982920623
- Cited by
- 1,560
- References
- 31
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 29 · 2019: 16 · 2018: 28 · 2017: 40 · 2016: 40 · 2015: 41 · 2014: 48 · 2013: 58 · 2012: 58
- FWCI
- 129.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- losartan, atenolol, hypertension, diabetes mellitus, left ventricular hypertrophy, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, ACE inhibitors, beta-blockers, LIFE trial, stroke, myocardial infarction, all-cause mortality, blood pressure reduction, Framingham risk score, electrocardiogram
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.